0000950170-25-105036
SEC filingFirst meaningful revenues of $1.7M in Q2 2025, but net loss expanded to $144.2M due to warrant revaluation and ramp-up costs.
For the three months ended June 30, 2025, PureCycle reported its first meaningful revenues of $1.7 million, compared to zero in the same period last year, driven by initial sales from the Ironton Facility. However, total operating expenses increased to $47.2 million from $39.9 million, primarily due to a $7.8 million rise in cost of operations. This increase included a $3.7 million loss on disposal of fixed assets, $2.6 million higher production-related costs from the ramp-up, and $1.8 million higher employee expenses, partially offset by lower facilities costs. Research and development expenses decreased by $0.2 million, while selling, general and administrative expenses fell $0.3 million, driven by lower legal costs ($3.8 million) partially offset by higher equity-based compensation ($3.1 million).
The operating loss widened to $45.6 million from $39.9 million. Net loss soared to $144.2 million from $48.2 million, mainly due to an $82.3 million unfavorable change in fair value of liability-classified warrants, driven by an increase in the company's stock price. Interest expense rose $5.6 million to $17.6 million due to new revenue bond issuance. Other income of $0.6 million in Q2 2025 contrasted with other expense of $1.1 million in Q2 2024, driven by a gain on the Series A preferred put option.
PureCycle operates as a single segment focused on its dissolution recycling technology. No segment-level breakdown is provided, as the company is in early commercialization with one facility (Ironton) undergoing commissioning. The MD&A emphasizes the ramp-up of production at Ironton and future expansion plans.
Management highlighted several strategic priorities: the Ironton Facility is not yet at full capacity, but commissioning continues. The company outlined an ambitious growth plan leveraging the $300 million Series B preferred stock raise. Key milestones include: (1) beginning construction of a 130 million pound recycling facility in Thailand in H2 2025, with expected operational date mid-2027; (2) advancing permitting for a 130 million pound plant in Antwerp, Belgium (operational 2028); and (3) building a 300 million pound multi-line facility in Augusta, Georgia, with first purification line operational in 2029. Additionally, PureCycle received an FDA Letter of No Objection in July 2025, expanding process conditions for its PureFive™ resin. The company expects revenue growth as customer trials progress but acknowledges ongoing operating losses and reliance on external funding. Liquidity remains strong with $284.1 million cash and an undrawn $200 million revolving credit facility. No specific quantitative guidance for future periods was provided.
Total cash and equivalents of $284.1M, up from $15.7M at year-end 2024, driven by the $300M Series B preferred issuance. Working capital improved markedly; current assets rose to $314.9M from $53.9M. Total debt of $375.6M includes $250M Green Convertible Notes, $116.7M related-party bonds, and $31.9M third-party revenue bonds. Shareholders' equity decreased to $98.9M due to large net losses, but mezzanine equity (Series B preferred) now stands at $294.1M. Restricted cash of $13.9M is split between current and noncurrent. The going concern doubt was alleviated by the Series B raise.
No material purchase commitments for inventory or supply contracts were disclosed. A surety bond of $8.1M (reduced from $45.9M) provides financial assurance for a vendor contract through December 2025. Lease obligations are immaterial relative to asset base. The company faces litigation (Denham-Blythe arbitration) with a claim of ~$17M, but no loss provision has been recorded. Remaining principal payments on long-term debt and related-party bonds total $308.4M and $116.7M, respectively, with $250M Green Convertible Notes maturing in 2030.
Share repurchases totaled $2.8M for 0.3M shares in the first half of 2025, funded by common stock issuance. No common dividends were paid; Series B preferred dividends of $0.6M were paid in kind. Debt activity included net issuance of $28.9M, primarily from revenue bond sales to third parties ($16.8M) and related parties ($10.1M), along with a $10M draw and immediate repayment on the Sylebra revolver. Capital expenditures of $23.6M focused on the Ironton and Thailand facilities. The company also redirected $195M of long-lead equipment to Belgium/Thailand projects.
The company operates as a single segment focused on polypropylene recycling. Discrete financial information for sub-segments is not reviewed by the CODM; consolidated metrics are used. No geographic revenue breakdown is provided. The only revenue of $3.2M year-to-date comes from product sales at the Ironton Facility. The company is pre-commercialization, with ongoing construction in Thailand and design work for Augusta.
PureCycle's cash flow from operations (CFO) remained negative at -$75.6M for the six months ended June 30, 2025, a slight improvement from -$79.6M in the prior year. The net loss of $135.4M was larger than CFO, but non-cash charges (equity-based compensation, depreciation, warrant fair value changes) totaling $63.7M helped narrow the gap. Working capital changes consumed $3.9M, primarily driven by inventory build ($2.7M) and accounts receivable ($2.1M), partially offset by prepaid assets and accrued interest.
Capex of $23.6M was flat year-over-year, indicating ongoing investment in plant and equipment. The company did not generate free cash flow; the negative CFO and capex resulted in a cash burn of $99.2M from operations and investing. Financing activities provided $355.6M, largely from a $300M Series B preferred stock issuance and $33.3M from common stock issuance, offsetting the cash burn and resulting in a net cash increase of $256.4M. Share repurchases totaled $2.8M.
Notable non-cash items include impairment of operating right-of-use assets ($0.8M in 2024) and loss on extinguishment of debt ($21.2M in 2024). The company's cash position strengthened significantly, ending at $297.9M compared to $23.5M a year ago, driven by the equity raise.